| Trial ID: | L6348 |
| Source ID: | NCT04135287
|
| Associated Drug: |
Glp-1 Receptor Agonist
|
| Title: |
Relationship Between Improvement in Insulin Secretion and Decrease in HbA1c in GLP-1 RA Therapy in T2DM Patients
|
| Acronym: |
|
| Status: |
UNKNOWN
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus, Type 2
|
| Interventions: |
DRUG: GLP-1 receptor agonist
|
| Outcome Measures: |
Primary: HbA1c, Change in HbA1c from baseline to 6 months, 6 months | Secondary: Beta cell function, Change in Beta cell function measured as ∆C-Pep/(∆G/IR) and glucose sensitivity during OGTT, 6 months|Weight loss, Change in body weight from baseline to 6 months, 6 months|Fasting Plasma Glucagon, Change in FPG from baseline to 6 months, 6 months
|
| Sponsor/Collaborators: |
Sponsor: Dasman Diabetes Institute
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
315
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2020-03-01
|
| Completion Date: |
2023-07-15
|
| Results First Posted: |
|
| Last Update Posted: |
2020-07-21
|
| Locations: |
Dasman Diabetes Institute, Kuwait, 15462, Kuwait
|
| URL: |
https://clinicaltrials.gov/show/NCT04135287
|
